Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cleared the single pill combining conjugated estrogens with bazedoxifene, a novel selective estrogen receptor modulator, for two indications but issued a “complete response” letter for use in vulvar and vaginal atrophy.
You may also be interested in...
FDA Shutdown Plans For 2015: Same As 2013, But With More People
'Limited activities related to user fee funded programs' will continue if Congress does not pass a short-term funding measure by Oct. 1.
European Backing For AstraZeneca’s Olaparib Bolsters Barriers To Pfizer
Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.
FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs
As normal operations – and normal budget worries – resume, the agency has some meetings to reschedule.